Joshi Shashank, Vora Agam, Venugopal K, Dadhich Pramod, Daxini Anil, Bhagat Sagar, Patil Saiprasad, Barkate Hanmant
Department of Endocrinology, Joshi Clinic and Lilavati Hospital and Research Centre, Mumbai, India.
Department of Pulmonology, Vora Clinic, Mumbai, India.
Pragmat Obs Res. 2022 May 27;13:33-41. doi: 10.2147/POR.S364066. eCollection 2022.
Favipiravir, an RNA-dependent RNA polymerase inhibitor (RdRp), is a broad-spectrum oral antiviral agent approved in India under emergency use authorization, for the treatment of mild-to-moderate coronavirus disease (COVID-19). The present study was planned to evaluate the effectiveness and safety of favipiravir in real-world clinical practice.
This was a multicentric, retrospective, single-arm study conducted across four centres in India, after obtaining permission from the independent ethics committee. Medical records were analysed to evaluate effectiveness and safety of patients who were prescribed favipiravir.
The medical records of a total of 360 patients met the inclusion criteria, with 358 of them available for the final analysis. Males made up 58.46% of the study population. The average age of enrolled patients was 51.80 ± 16.45 years. The most common symptoms were fever, cough, and myalgia-fatigue. The median time to clinical cure and fever relief was five and four days, respectively. The average length of stay in the hospital was six days. In total, 8% of the patients experienced adverse events. Hepatic enzyme elevation, diarrhoea, decreased appetite, headache, fatigue, and giddiness were the common symptoms.
In our real-world study, favipiravir was found to have a clinical cure rate of more than 90% in mild-to-moderate COVID-19 patients. This supports the use of favipiravir in the treatment of COVID-19. Favipiravir was well tolerated, with only minimal side effects, which were transient in nature.
法匹拉韦是一种RNA依赖性RNA聚合酶抑制剂（RdRp），是一种在印度获得紧急使用授权批准的广谱口服抗病毒药物，用于治疗轻至中度冠状病毒病（COVID-19）。本研究旨在评估法匹拉韦在实际临床实践中的有效性和安全性。
这是一项多中心、回顾性、单臂研究，在获得独立伦理委员会许可后，于印度的四个中心开展。对病历进行分析，以评估开具法匹拉韦处方患者的有效性和安全性。
共有360例患者的病历符合纳入标准，其中358例可供最终分析。男性占研究人群的58.46%。入选患者的平均年龄为51.80±16.45岁。最常见的症状是发热、咳嗽和肌痛-疲劳。临床治愈和退热的中位时间分别为5天和4天。平均住院时间为6天。总共有8%的患者发生不良事件。肝酶升高、腹泻、食欲减退、头痛、疲劳和头晕是常见症状。
在我们的实际研究中，发现法匹拉韦在轻至中度COVID-19患者中的临床治愈率超过90%。这支持法匹拉韦用于治疗COVID-19。法匹拉韦耐受性良好，只有轻微副作用，且为一过性。
